- Home
- HTD vs AQST Comparison
HTD vs AQST Comparison
Compare HTD & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTD
- AQST
- Stock Information
- Founded
- HTD 2004
- AQST 2004
- Country
- HTD United States
- AQST United States
- Employees
- HTD N/A
- AQST N/A
- Industry
- HTD Finance Companies
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- HTD Finance
- AQST Health Care
- Exchange
- HTD Nasdaq
- AQST Nasdaq
- Market Cap
- HTD 863.8M
- AQST 809.3M
- IPO Year
- HTD N/A
- AQST 2018
- Fundamental
- Price
- HTD $24.60
- AQST $6.48
- Analyst Decision
- HTD
- AQST Strong Buy
- Analyst Count
- HTD 0
- AQST 6
- Target Price
- HTD N/A
- AQST $10.33
- AVG Volume (30 Days)
- HTD 92.3K
- AQST 3.1M
- Earning Date
- HTD 01-01-0001
- AQST 11-05-2025
- Dividend Yield
- HTD 8.59%
- AQST N/A
- EPS Growth
- HTD N/A
- AQST N/A
- EPS
- HTD N/A
- AQST N/A
- Revenue
- HTD N/A
- AQST $44,132,000.00
- Revenue This Year
- HTD N/A
- AQST N/A
- Revenue Next Year
- HTD N/A
- AQST $51.39
- P/E Ratio
- HTD N/A
- AQST N/A
- Revenue Growth
- HTD N/A
- AQST N/A
- 52 Week Low
- HTD $16.17
- AQST $2.12
- 52 Week High
- HTD $22.13
- AQST $7.55
- Technical
- Relative Strength Index (RSI)
- HTD 47.16
- AQST 51.90
- Support Level
- HTD $24.46
- AQST $6.63
- Resistance Level
- HTD $25.20
- AQST $7.18
- Average True Range (ATR)
- HTD 0.31
- AQST 0.39
- MACD
- HTD -0.04
- AQST -0.11
- Stochastic Oscillator
- HTD 32.58
- AQST 7.76
About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, telecommunication services, industrials, healthcare, real estate, consumer discretionary and short-term investments.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.